
About Enlivex Pharmaceuticals
Enlivex Pharmaceuticals is a publicly listed company based in Jerusalem (Israel) founded in 2005. Autologous and allogeneic cell immunotherapies are developed for autoimmune conditions. Enlivex Pharmaceuticals has raised $7 million across 4 funding rounds from investors including Korea Investment Holdings and Hadasit. The company has 36 employees. Its chief executive, as recorded, is Oren Hershkovitz. Enlivex Pharmaceuticals offers products and services including Allocetra. Its focus areas include Life Sciences, Cell Therapy, Somatic Cells and Immunology. Its legal entity is Enlivex Therapeutics Ltd.
Company details
Enlivex Pharmaceuticals, a cell immunotherapy company, is developing an autologous and allogeneic drug pipeline for the treatment of autoimmune and inflammatory conditions. Its clinical development programs focus on GvHD (graft versus host disease), CAR-T, and autoimmune diseases; Allocetra, has been developed for the prevention of acute GvHD (Phase 23), particularly severe, or high-grade, acute GvHD (orphan drug designation); Allocetra consists of retrieving a blood sample from the patient or a matched donor, treating it at the cellular level to generate an early apoptotic cell population undergoing apoptosis and injecting it into the patient; Enlivex is also examining the potential for collaborating with leading CAR-T companies in clinical studies to evaluate the efficacy and side effect profile of CAR-T treatments for a variety of cancer-related clinical indications, such as blood cancers and solid tumors.
- Headquarters Jerusalem, Israel
- Employees 36
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website enlivex.com
- Social LinkedIn X
- Legal Name Enlivex Therapeutics Ltd.
- Net Profit$1.24 B (USD)as on Dec 31, 2025
- EBITDA-$14.67 M (USD)2.15as on Dec 31, 2025
- Total Equity Funding$7M (USD)
in 4 rounds
- Latest Funding Round$212M (USD), Post-IPO
Nov 2025
- InvestorsKorea Investment Holdings
& 1 more
- Employee Count36
Products & Services of Enlivex Pharmaceuticals
Enlivex Pharmaceuticals offers a comprehensive portfolio of products and services, including Allocetra.
Off-the-shelf therapy for treating inflammatory diseases via clinical applications
Funding Insights of Enlivex Pharmaceuticals
Enlivex Pharmaceuticals has successfully raised a total of $7M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $212 million completed in November 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $7M
- Total Rounds 4
- Last Round Post-IPO β $212M
- First Round $7M
(May 2014)
- Investors Count 2
All 4 funding rounds of Enlivex Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2025 | $212M | Post-IPO | β | β | β |
| Apr 2019 | $8.4M | Post-IPO | β | β | β |
| Sep 2017 | $8M | Post-IPO | β | β | |
| May 2014 | $7M | Series A | β | β | β |
2 investors in total: 2 institutional.
Investors in Enlivex Pharmaceuticals
Enlivex Pharmaceuticals has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include Korea Investment Holdings and Hadasit.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investment holding firm established in Seoul in 2003. | 2003 | koreainvestment.com | Seoul, South Korea | |
| hadasit.org.il |
Investor details for Enlivex Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Enlivex Pharmaceuticals
1 people are tracked at Enlivex Pharmaceuticals (1 in leadership); the tracked headcount is 36.
| Name | Role | Group |
|---|---|---|
Oren Hershkovitz | CEO | Leadership |
Complete people profiles for Enlivex Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Enlivex Pharmaceuticals
Enlivex Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol ENLV in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date31 Jul 2014
- Listed onNASDAQ: ORPN
- Listed entityEnlivex Therapeutics Ltd.
- Exchange sectorHealth technology
- ISINIL0011319527
- Share price$0.22 (-12.09% on the day) · 2026-10-13
- Market capitalisation$4.4M
- Volume (last session)873,964
Financials of Enlivex Pharmaceuticals
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $1.24B | -$14.7M | |
| 2024 | -$15.0M | -$15.0M | |
| 2023 | -$29.1M | -$24.1M | |
| 2022 | -$31.1M | -$23.8M | |
| 2021 | -$14.5M | -$17.7M |
Detailed financial statements for Enlivex Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Enlivex Pharmaceuticals
4 dated milestones of Enlivex Pharmaceuticals across 20 years, from founding to its latest funding, stage changes and deals.
- Founded Enlivex Pharmaceuticals is founded.
- Funding First funding round of $7.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $212.0M.
Web traffic of Enlivex Pharmaceuticals
The website of Enlivex Pharmaceuticals (enlivex.com) receives about 6.9K visits a month and ranks #2,471,947 among all websites worldwide, #3,395 in Biotechnology and Pharmaceuticals.
- Monthly visits6.9K
▼ 25.8% vs previous month
- Unique visitors4.5K
per month
- Global rank#2,471,947
among all websites
- Category rank#3,395
Health · Biotechnology and Pharmaceuticals
- Bounce rate40%
- Pages per visit1.5
- Average visit17 sec
- DevicesDesktop 28% Β· Mobile 72%
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Enlivex Pharmaceuticals
Complete news archive for Enlivex Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Enlivex Pharmaceuticals
Enlivex Pharmaceuticals was founded in 2005 and raised its 1st funding round 9 years after it was founded.
Enlivex Pharmaceuticals is headquartered in Jerusalem, Israel. It is registered at Jerusalem, Jerusalem District, Israel.
Oren Hershkovitz is the CEO of Enlivex Pharmaceuticals, as recorded in our data.
Enlivex Pharmaceuticals is a funded company, having raised a total of $7M across 4 funding rounds to date. The company's 1st funding round was a Series A of $7M, raised on May 2014.
Enlivex Pharmaceuticals has 36 employees.
Enlivex Pharmaceuticals, a cell immunotherapy company, is developing an autologous and allogeneic drug pipeline for the treatment of autoimmune and inflammatory conditions. Its clinical development programs focus on GvHD (graft versus host disease), CAR-T, and autoimmune diseases; Allocetra, has been developed for the prevention of acute GvHD (Phase 23), particularly severe, or high-grade, acute GvHD (orphan drug designation); Allocetra consists of retrieving a blood sample from the patient or a matched donor, treating it at the cellular level to generate an early apoptotic cell population undergoing apoptosis and injecting it into the patient; Enlivex is also examining the potential for collaborating with leading CAR-T companies in clinical studies to evaluate the efficacy and side effect profile of CAR-T treatments for a variety of cancer-related clinical indications, such as blood cancers and solid tumors.
Enlivex Pharmaceuticals offers Allocetra.
Yes, Enlivex Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol ENLV.
Enlivex Pharmaceuticals has 2 investors. Key investors include Korea Investment Holdings, and Hadasit.
Enlivex Pharmaceuticals operates through Enlivex Therapeutics Ltd..
